Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER) –positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase II...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Lin, Li, Snider, Jacqueline, Prat, Aleix, Parker, Joel S., Luo, Jingqin, DeSchryver, Katherine, Allred, D. Craig, Esserman, Laura J., Unzeitig, Gary W., Margenthaler, Julie, Babiera, Gildy V., Marcom, P. Kelly, Guenther, Joseph M., Watson, Mark A., Leitch, Marilyn, Hunt, Kelly, Olson, John A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2011
विषय:
Original Reports
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107749/
https://ncbi.nlm.nih.gov/pubmed/21555689
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.6950
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन